CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025)
CapsoVision (CV) posted Preferred Stock Liabilities of $143.6 million for Q2 2025, little changed sequentially from $143.6 million in Q4 2024, and up 11.66% YoY from $128.6 million in Q2 2024.
CapsoVision (CV) Preferred Stock Liabilities (2024 - 2025) Analysis & Trends
CapsoVision has reported Preferred Stock Liabilities for 2 years, with the latest figure at $143.6 million in Q2 2025.
- Quarterly Preferred Stock Liabilities rose 11.66% year-over-year to $143.6 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $143.6 million (up 11.66% YoY) and the FY2024 annual result came in at $143.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $143.6 million in Q2 2025 per CV's latest filing, from $143.6 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $143.6 million in Q4 2024 and troughed at $128.6 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | - |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | - |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | - |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | - |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | - |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | - |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | - |
| 10 | CapsoVision | 295.13 Mn | 286.05 Mn | 1.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 143.63 Mn |
| Dec 31, 2024 | 143.63 Mn |
| Sep 30, 2024 | 138.63 Mn |
| Jun 30, 2024 | 128.63 Mn |